ANCA-NUCLEOTIDASE 2: A Potential Drug Target and Biomarker for Autoimmune Diseases

Target Name: ANAPC2

NCBI ID: G29882

ANAPC2

ANCA-NUCLEOTIDASE 2: A Potential Drug Target and Biomarker for Autoimmune Diseases

ANAPC2 (ANCA-NUCLEOTIDASE 2) is a gene that encodes a protein known as ANCA-NUCLEOTIDASE 2. This gene is located on chromosome 16 and has been implicated in a number of autoimmune diseases, including systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect multiple organs and systems in the body.

ANCA-NUCLEOTIDASE 2 is a enzyme that is involved in the breakdown of a type of sugar called nucleotides. Nucleotides are the building blocks of DNA and RNA and are essential for the functioning of the immune system. However, in diseases such as SLE, the immune system becomes abnormally active and attacks the body's own tissues, leading to inflammation and damage.

ANCA-NUCLEOTIDASE 2 has been shown to play a role in the regulation of the immune response and has been identified as a potential drug target in the treatment of autoimmune diseases. Studies have shown that ANCA-NUCLEOTIDASE 2 is expressed in a variety of tissues and cells in the body, including the liver, spleen, and lymphocytes. It is also highly expressed in the blood, which suggests that it may be a useful biomarker for monitoring disease activity.

In addition to its potential as a drug target, ANCA-NUCLEOTIDASE 2 is also of interest as a potential biomarker for tracking disease progression in autoimmune diseases. The levels of ANCA-NUCLEOTIDASE 2 in body tissues, such as the liver and spleen, have been shown to be reduced in individuals with active autoimmune diseases, such as SLE. This suggests that ANCA-NUCLEOTIDASE 2 may be a useful diagnostic tool for tracking disease progression and response to treatment.

Furthermore, ANCA-NUCLEOTIDASE 2 has also been shown to play a role in the regulation of inflammation. Studies have shown that ANCA-NUCLEOTIDASE 2 is involved in the production of pro-inflammatory cytokines, which are molecules that contribute to inflammation. This suggests that ANCA-NUCLEOTIDASE 2 may be a potential target for anti-inflammatory therapies.

In conclusion, ANAPC2 (ANCA-NUCLEOTIDASE 2) is a gene that has been implicated in a number of autoimmune diseases. It is expressed in a variety of tissues and cells in the body and has been shown to play a role in the regulation of the immune response, disease progression, and inflammation. As a result, ANCA-NUCLEOTIDASE 2 is a potential drug target and biomarker for the treatment of autoimmune diseases. Further research is needed to fully understand the role of ANCA-NUCLEOTIDASE 2 in autoimmune diseases and to develop effective treatments.

Protein Name: Anaphase Promoting Complex Subunit 2

Functions: Together with the RING-H2 protein ANAPC11, constitutes the catalytic component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. The CDC20-APC/C complex positively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. CDC20-APC/C-induced degradation of NEUROD2 drives presynaptic differentiation

The "ANAPC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANAPC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets